Skip to main content

Table 2 Epidemic profiles of hepatitis B and C infection in the countries covered by the survey

From: Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries

HBV epidemiology Country number (%) and name
High seroprevalence (>5%) in general population 12 (54.5%)
Gambia, Thailand, Chad, Mongolia, Côte d’Ivoire, Vietnam, Niger, Uganda, Hong Kong SAR/China, Democratic Republic of the Congo, Tanzania, Kenya
Intermediate seroprevalence (3-5%) in general population 3 (13.6%)
Fiji, Philippines, Myanmar
Low seroprevalence (<3%) in general population 3 (13.6%)
Ukraine, India, Georgia
HCV epidemiology based on anti-HCV antibody Country number (%) and name
High seroprevalence (>3%) in general population and concentrated epidemic among PWID 3 (13.6%)
Georgia, Mongolia, Ukraine
Intermediate/low seroprevalence (1-3%) in general population but concentrated epidemic among PWID 5 (22.7%)
India, Philippines, Thailand, Myanmar, Vietnam
Low seroprevalence (<1%) in general population 9 (40.9%)
Chad, Côte d’Ivoire, Democratic Republic of the Congo, Gambia, Hong Kong SAR/China, Kenya, Niger, Tanzania, Uganda
  1. Source: [58,59,60,61,62,63,64,65,66,67,68,69,70]; the HCV prevalence data provided by the respondents are presented for Côte d’Ivoire, Mongolia, Niger, Philippines, Togo and Uganda as no published data is available from these countries